TY - JOUR AU - Parente, Bárbara PY - 2018/02/22 Y2 - 2024/03/29 TI - Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: State of the Art: Estado da Arte dos Doentes com Cancro do Pulmão de Não Pequenas Células: Doença Avançada e Mutação EGFR Positiva JF - Gazeta Médica JA - Gaz Med VL - 3 IS - 2 SE - RECENT ADVANCEMENTS DO - 10.29315/gm.v3i2.111 UR - https://www.gazetamedica.pt/index.php/gazeta/article/view/111 SP - AB - <p>The emergence of targeted therapies, brought in the last decade a large hope for patients with lung cancer. EGFR tyrosine kinase inibitors, (TKI) erlotinib and gefitinib, changed the last 10 years the practice of treatment for advanced non-small-cell lung cancer (NSCLC) with the discovery of EGFR mutations that confer sensitivity to tyrosine kinase inhibitors in NSCLC.</p><p>The year of 2004 marked the Era of Precision Medicine for lung cancer. The studies randomized phase III investigated the role of two inhibitors of EGFR-TKI, gefitinib and erlotinib, as the treatment of first line compared with platinum-based chemotherapy in NSCLC patients with advanced disease, EGFR activating mutations.</p><p>A second generation TKI (afatinib) is already approved for the same indication (EMA) with the good results of the clinical trials, Lux Lung 3 and 6. However patients with EGFR positive mutation, usually have a progressive disease after 10-12 months, with need of new treatment options. Inhibitors third generation however developed (for resistance mutation, T790M and others, after rebiopsy), demonstrated a remarkable efficacy in patients already treated, and with a toxicity profile better than TKI of 1st and 2nd generation.</p><p>Received: 30/05/2016 - Accepted: 03/06/2016</p> ER -